Angiotensin I-Converting Enzyme Inhibitory Activity of Peptides Derived from Egg White Proteins by Enzymatic Hydrolysis (original) (raw)
Related papers
Journal of Dairy Science, 2015
The occurrence of 8 bovine casein-derived peptides (VPP, IPP, RYLGY, RYLG, AYFYPEL, AYFYPE, LHLPLP, and HLPLP) reported as angiotensin converting enzyme-inhibitors (ACE-I) was investigated in the 3-kDa ultrafiltered water-soluble extract (WSE) of Parmigiano Reggiano (PR) cheese samples by ultraperformance liquid chromatography coupled to highresolution mass spectrometry via an electrospray ionization source. Only VPP, IPP, LHLPLP, and HLPLP were revealed in the WSE, and their total amount was in the range of 8.46 to 21.55 mg/kg of cheese. Following in vitro static gastrointestinal digestion, the same ACE-I peptides along with the newly formed AYFYPEL and AYFYPE were found in the 3 kDa WSE of PR digestates. Digestates presented high amounts (1,880-3,053 mg/kg) of LHLPLP, whereas the remaining peptides accounted for 69.24 to 82.82 mg/kg. The half-maximal inhibitory concentration (IC 50) values decreased from 7.92 ± 2.08 in undigested cheese to 3.20 ± 1.69 after in vitro gastrointestinal digestion. The 3-kDa WSE of digested cheeses were used to study the transport of the 8 ACE-I peptides across the monolayers of the Caco-2 cell culture grown on a semipermeable membrane of the transwells. After 1 h of incubation, 649.20 ± 148.85 mg/ kg of LHLPLP remained in the apical compartment, whereas VPP, IPP, AYFYPEL, AYFYPE, and HLPLP accounted in total for less than 36.78 mg/kg. On average, 0.6% of LHLPLP initially present in the digestates added to the apical compartment were transported intact to the basolateral chamber after the same incubation time. Higher transport rate (2.9%) was ascertained for the peptide HLPLP. No other intact ACE-I peptides were revealed in the basolateral compartment. For the first time, these results demonstrated that the ACE-I peptides HLPLP and LHLPLP present in the in vitro digestates of PR cheese are partially absorbed through an in vitro model of human intestinal epithelium.
International Dairy Journal, 2002
Food products containing angiotensin converting enzyme (ACE) inhibitory peptides reportedly play a role in treatment of mild hypertension. The aim of this placebo-controlled crossover study was to assess the bioavailability of Ile-Pro-Pro and 7 other ACE-inhibiting peptides present in a lactotripeptide (LTP)-enriched yogurt beverage and whether meal intake affects Ile-Pro-Pro bioavailability. Six male and female subjects randomly consumed an LTP-enriched yogurt beverage or a placebo in the fasted state and an LTP-enriched yogurt beverage in the fed or fasted state. The area under the curve (AUC) of Ile-Pro-Pro after the LTP treatment in the fasted state was 2.1-fold of that after the placebo treatment (P , 0.001). The maximum peptide plasma concentration (C max ) value was greater after consumption of the LTP-enriched beverage (897 6 157 pmol/L) than after the placebo treatment (555 6 0.09 pmol/L; P , 0.001) with a greater time after ingestion when reaching C max (T max ) in the placebo treatment. Plasma concentrations of the peptides Leu-Trp, Phe-Tyr, Ile-Tyr, and Leu-Pro-Pro increased compared with baseline (P , 0.05) in the LTP-enriched and placebo treatment when consumed in the fasted state. However, DC max values differed significantly between the placebo and LTP-enriched treatment only for Leu-Pro-Pro. Meal intake affected Ile-Pro-Pro concentrations. When the beverage was consumed after a meal, the AUC of Ile-Pro-Pro was 1.3-fold (P , 0.05) of the AUC derived from premeal intake. This was due to an increase in the plasma elimination half-life (P , 0.05); C max and T max were not affected by meal intake. In summary, this is the first demonstration, to our knowledge, that the tripeptide Ile-Pro-Pro selectively escapes from intestinal degradation and reaches the circulation undegraded. J. Nutr. 137: 953-958, 2007. . 2 Abbreviations used: ACE, angiotensin converting enzyme; AUC, area under the curve; C max , maximum peptide plasma concentration; LC-MRM-MS, liquid chromatography-multi reaction ion monitoring-mass spectrometry; LTP, lactotripeptide; T max , time after ingestion when reaching C max ; t 1/2 ; time in linear elimination phase in which peptide plasma concentration is halved.
Journal of the Science of Food and Agriculture, 2005
In vitro gastrointestinal digestion of pea and whey protein produced high angiotensin I converting enzyme (ACE) inhibitory activity with IC 50 values of 0.070 and 0.041 mg protein ml −1 respectively. Ultrafiltration/centrifugation using a membrane with a molecular weight cut-off of 3000 Da decreased the IC 50 value to 0.055 mg protein ml −1 for pea permeate and 0.014 mg protein ml −1 for whey permeate. Further fractionation by reverse phase HPLC gave IC 50 values as low as 0.016 mg protein ml −1 for pea and 0.003 mg protein ml −1 for whey. Consequently, these purification steps enriched the ACE inhibitory activity of the pea digest more than four times and that of the whey digest more than 13 times. HPLC profiles after digestion and ultrafiltration indicate that high ACE inhibitory activity is due to short and more hydrophobic peptides. The results also suggest that potent ACE inhibitory peptides were present alongside low active peptides in whey hydrolysate, while all peptides had more or less the same ACE inhibitory activity in pea hydrolysate. In addition, the hydrolysates and enriched fractions will resist in vivo gastrointestinal digestion after oral administration. Hence these ACE inhibitory peptides, as part of functional foods, can play significant roles in the prevention and treatment of hypertension.
Journal of Agricultural and Food Chemistry, 2007
In this study, we have identified novel antihypertensive peptides derived from egg-white proteins. The sequences YRGGLEPINF and ESIINF produced an acute blood-pressure-lowering effect in spontaneously hypertensive rats upon a single oral administration. Our results suggest that the antihypertensive action could be attributed to a vascular-relaxing mechanism that would occur in vivo independently of angiotensin I-converting enzyme (ACE) inhibition, because neither these peptides nor their main digestion fragments, except for the dipeptide YR, acted as ACE inhibitors in vitro. The vasodilator and antihypertensive activity of the sequences ESI and NF would explain the bloodpressure-lowering effect of ESIINF. With regard to YRGGLEPINF, in addition to NF, YR appeared as the main fragment responsible for its activity. The dipeptide YR, named kyotorphin and previously identified as an endogenous analgesic neuropeptide in the central nervous system, showed strong vasodilator and antihypertensive properties. The structure-activity features of the vasodilator peptides are discussed. DGSRQPV (ovotransferrin 230-236). The fragments resulting from the simulation of the gastrointestinal digestion of YRGGLEPINF and ESIINF (YRGGLEPI, YR, GGLEPI, ESI, and NF) were also synthesized. All of these peptides were obtained by conventional Fmoc solid-phase synthesis with a 431A peptide synthesizer (Applied Biosystem, Inc., Ü berlingen, Germany) according to the method described by Atherton and Sheppard (29). They were synthesized and provided by the Unitat de Pèptids of Barcelona University, and their purity (>90%) was verified in our laboratory by reversed-phase high-performance liquid chromatography-tandem mass spectrometry (RP-HPLC-MS/MS) (30). The drugs and the peptides were dissolved in distilled water for the reactivity experiments and administration to the rats.
Nutrition Research, 2004
Angiotensin I-converting enzyme (ACE) catalyzes the conversion of angiotensin I to vasoconstrictor angiotensin II, and also inactivates the antihypertensive vasodilator bradykinin. Inhibition of ACE mainly results in an overall antihypertensive effect. Peptides derived from food proteins can have ACE inhibiting properties. This article reviews the ACE inhibitory peptides derived from different food proteins. Some of the ACE inhibitory peptides exhibit significant antihypertensive effects. However, the inhibitory potencies of these peptides on ACE activity do not always correlate with their antihypertensive activities. Some peptides with high inhibitory activity on this enzyme in vitro have no blood pressure lowering effects, whereas some peptides with low inhibitory activity on this enzyme in vitro have such effects. The possible mechanisms for this conflicting phenomenon between inhibitory activity and antihypertensive effect, the structure-activity relationships, and the potential use prospect of these peptides in the development of a novel functional food for preventing hypertension as well as therapeutic purposes, are also discussed.
Le Lait, 2005
The angiotensin I converting enzyme (ACE) inhibitory activity of fermented blue mussel sauce (FBMS) was investigated. Blue mussels were fermented with 25% NaCl (w/w) at 20 degrees C for 6 months and the resultant mixture was passed through a 40-mesh sieve, desalted using an electrodialyzer and then lyophilized. The IC(50) value of FBMS for ACE activity was 1.01 mg/ml. An ACE inhibitory peptide was purified from FBMS using Sephadex G-75 gel chromatography, SP-Sephadex C-25 ion exchange chromatography and reversed-phase high-performance liquid chromatography on a C(18) column. The IC(50) value of purified ACE inhibitory peptide was 19.34 microg/ml, and 10 amino acid residues of the N-terminal sequence was EVMAGNLYPG. The purified peptide was evaluated for antihypertensive effect in spontaneously hypertensive rats (SHR) following oral administration. Blood pressure significantly decreased after peptide ingestion. This result suggested that FBMS may have beneficial effects on hypertension.
International Dairy Journal, 2004
The angiotensin converting enzyme (ACE)-inhibitory activity of several infant formulas was evaluated. Most of these products showed moderate inhibitory activity, but two exceptions that corresponded to an extensively hydrolysed whey formula and an extensively hydrolysed casein formula were detected. Two products (a non-hydrolysed milk protein-based formula and an extensively hydrolysed whey formula) were subjected to a two-stage in vitro enzymatic procedure, which simulates physiological digestion, in order to study the impact of digestion on ACE-inhibitory activity. The ACE-inhibitory activity of the non-hydrolysed formula increased during simulated gastrointestinal digestion, while no significant change was observed in the activity of the hydrolysed whey formula prior to and after, digestion. The peptides generated from these two products during simulated physiological digestion were sequenced by tandem spectrometry. At the end of the digestion, most peptides found in the nonhydrolysed milk protein-based formula were formed during incubation with the pancreatic extract, but, in the hydrolysed whey formula, many peptides present in the undigested product survived simulated digestion. The potential ACE-inhibitory activity of these peptides is discussed with regard to their amino-acid sequences. r
… Nutrition & Food …, 2011
The aim of this study was to investigate the antihypertensive effect of a peptide fraction (PepC) obtained from a whey protein concentrate following hydrolysis by Cynara cardunculus, as well as of its fraction with MW below 3 kDa (PepCF). Both these concentrates encompassed peptides that exhibited potent in vitro inhibition of angiotensin-converting enzyme (ACE): two were released from a-lactalbumin-KGYGGVSLPEW and DKVGINYW, and one from b-lactoglobulin-DAQSAPLRVY. Methods and results: Upon oral administration, by gastric intubation, of 400 mg/kg body weight (bw) of those peptide concentrates, or 5 mg/kg bw of the corresponding synthetic peptides, to 12 wk-old spontaneously hypertensive rats (SHR), the systolic and diastolic blood pressures were monitored by the tail-cuff method-before, and 2, 4, 6, 8 and 24 h afterwards. Water and zofenopril (5 mg/kg bw)-a known ACE-inhibitor, were used as negative and positive controls, respectively. Acute administration of PepC, PepCF, KGYGGVSLPEW, DKVGINYW and DAQSAPLRVY caused antihypertensive effects in SHR; the maximum effect occurred by 4 h and 6 h after administration of the peptide concentrates and the synthetic peptides, respectively. PepC and KGYGGVSLPEW also showed ACE-inhibitory activity in vivo: the pressor effect of angiotensin I was significantly lower, and the response to bradykinin increased when the rats were pre-treated with either product. Conclusion: Our results strongly suggest that PepC will be effective as nutraceutical ingredient for the formulation of functional foods aimed at hypertension control.
Journal of Food Science, 2000
Angiotensin I-converting enzyme (ACE)-inhibitory peptides from the thermolysin digest of chicken muscle and the peptic digest of ovalbumin were isolated. However, some of them failed to show antihypertensive activity in spontaneously hypertensive rats (SHR). To clarify this discrepancy, ACE-inhibitory peptides from various sources were preincubated with ACE before measurement of ACE-inhibitory activity and classified into 3 groups: (1) inhibitor type, IC 50 values of peptides that are not affected after preincubation with ACE;( 2) substrate type, peptides that are hydrolyzed by ACE to give peptides with weaker activity; and (3) prodrug-type inhibitor, these peptides are converted to true inhibitors by ACE or gastrointestinal proteases. Peptides belonging to the 1st and the 3rd groups exert antihypertensive activities even after oral administration in SHR.